Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07150624 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 28, 2026 to Dec 31, 2026
    • Study completion date: Mar 31, 2026 to Dec 31, 2026
    • Start date changed from estimate of Aug 30, 2025 to Nov 10, 2025
    • Eligibility criteria expanded, about 48 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hepatectomy for hepatocellular carcinoma were compared.
Trial Details
NCT Number NCT07150624
Lead Sponsor Anhui Provincial Hospital
Collaborators: The First Affiliated Hospital of Anhui Medical University, The Second Hospital of Anhui Medical University, The First Affiliated Hospital of Bengbu Medical University, First Affiliated Hospital of Wannan Medical College
Conditions
(from sponsor)		 Hepatocellular Carcinoma (HCC), Liver Diseases
Related terms Carcinoma, Hepatocellular, Liver Diseases
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov